Leukocytoclastic vasculitis due to ruxolitinib treatment: A rare adverse effect.
Mesut TığlıoğluPınar CömertAbdulkerim YıldızMerih Reis ArasBuğra SağlamHacer Berna Afacan ÖztürkAyşegül AdabağMurat AlbayrakPublished in: Journal of clinical pharmacy and therapeutics (2021)
To the best of our knowledge, leukocytoclastic vasculitis due to ruxolitinib is extremely uncommon. This case report can be considered to contribute to the literature of this rare event.